8-K ·Filed May 21, 2026

ZLAB

Zai Lab Ltd
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago SEC0001628280-26-037387
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any further management departures or strategic shifts in the next quarter. The lack of a named successor and immediate absorption of duties by the CEO suggests a potential restructuring or cost-saving move, but at current levels this is a routine organizational change for a $2.1B biopharma.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
ZLAB ▲ +37.40% at T+60d
NEUTRAL call ✓ call won +37.40% · α vs SPY +34.21% · entry $18.61 → $25.57
Entry anchored
May 21, 2026
via day open
T+1d
-0.86%
call -0.86% · α -1.45%
$18.45
settled 4mo ago
T+5d
-8.17%
call -8.17% · α -9.83%
$17.09
settled 4mo ago
T+20d
-0.97%
call -0.97% · α +0.45%
$18.43
settled 3mo ago
T+60d
+37.40%
call +37.40% · α +34.21%
$25.57
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Zai Lab's President and COO Josh Smiley is departing effective immediately, with his last day on May 22, 2026. Responsibilities are being absorbed by CEO Samantha Du and the existing management team, with no named replacement. While a single C-suite departure is notable, the company has a strong analyst consensus (79% bullish) and the CEO/founder is directly stepping in, mitigating disruption risk.

Key Facts

  • President and COO Josh Smiley ceases role effective May 18, 2026, last day May 22, 2026
  • No replacement named; CEO Samantha Du and management team assume responsibilities
  • Severance provided per existing employment agreement subject to customary release
  • Filed on Form 8-K with only Item 5.02 (officer departure)

Financial Impact

No financial figures disclosed in the filing

Risk Factors

  • If additional key executives depart, it may signal broader organizational instability
  • No clear succession plan may create temporary operational gaps

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-037387
Document: 0001628280-26-037387-index-headers.html0001628280-26-037387
Document: 0001628280-26-037387-index.html0001628280-26-037387
Document: 0001628280-26-037387.txt0001628280-26-037387
20 reports for ZLAB
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +13.13%May 7, 2026
Filters
Rows
Reports for ZLAB — sortable, filterable
TypeNow
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.01 $26.08▲ +0.27%▼ −0.20%$24.33 (−6.46%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.03 $26.02▼ −0.04%▲ +1.93%$24.33 (−6.53%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.03 $26.02▼ −0.04%▲ +1.93%$24.33 (−6.53%)
Aug 12, 2026
7w ago
144
NEUTRAL ★ 2/10
$25.49 $26.72▲ +4.83%▲ +5.27%$24.33 (−4.55%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$19.15 $19.35▲ +1.04%▲ +0.78%$24.33 (+27.05%)
Jun 29, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$19.00 $19.08▲ +0.42%▼ −0.18%$24.33 (+28.05%)
Jun 11, 2026
16w ago
Institutional Cluster
BEARISH ★ 5/10
$17.64 $17.88▼ −1.36%▼ −0.93%$24.33 (−37.93%)
May 21, 2026
19w ago
8-K
NEUTRAL ★ 4/10
$18.61 $17.09▼ −8.17%▼ −9.83%$24.33 (+30.74%)
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 3/10
$18.81 $18.69▼ −0.64%▼ −1.88%$24.33 (+29.35%)
May 19, 2026
19w ago
Insider Cluster
BEARISH ★ 6/10
$18.81 $18.69▲ +0.64%▲ +1.88%$24.33 (−29.35%)
Showing 10 of 20

US Market Status

Market Closed — Opens Mon (39h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access